flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk 🚨 Journal Club: FLOW Trial – ADA 24: FLOW Trial: Kidney

While Medicare already covered the peptide GLP-1 for those with diabetes and cardiovascular disease, the agencys move to establish an 18-month pilot program allows the elderly and the disabled to use branded forms of the drug including Ozempic, Wegovy and Zepbound for weight-loss purposes

This is because acetaminophen is not an NSAID, or a nonsteroidal anti-inflammatory drug, which cause birth defects

The bottom line In the race to see who can live the longest and healthiest, OTC compounds like methylene blue often gain intense attention

And so when you talk about, you know, if somebody is experiencing pain, we know that that physical pain, we know that thats such a vagus nerve disrupter

Bottom line: MeAgain is built for the full daily GLP-1 journey not just medication-cycle interpretation